Armetheon, Inc., is a privately held San Francisco Bay area
based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company
was founded by three successful biotech entrepreneurs and pharmaceutical executives with several years of drug R&D
and company building experience.
|
Core development
program:
|
|
Tecarfarin
(ATI-5923)
|
Potentially best-in-class, late clinical trial stage, novel safe and effective orally active
anti-coagulant. It is a potent inhibitor of VKOR that is not metabolized by CYP2C9 enzyme and,
hence, has a superior profile to warfarin. Unlike, non-monitored oral anti-coagulant drugs that are
direct inhibitors of thrombin or Factor Xa, tecarfarin can be used in patients with (i) prosthetic
heart valves, and/or (ii) who have renal dysfunction.
|
| |
|
|
Non-Core development
programs:
|
Naronapride
(ATI-7505) |
Potentially best-in-class, late clinical trial stage, novel safe and effective orally active
5HT4 agonist for gastrointestinal (GI) disorders. These include upper GI (such as sGERD,
PPI-resistant GERD, gastroparesis) and lower GI (such as chronic constipation) disorders.
|
Budiodarone
(ATI-2042) |
Potentially best-in-class, mid-clinical trial stage, novel safe and effective anti-arrhythmic
agent (both oral and intravenous) for the treatment of patients with atrial fibrillation.
|
|
|
|
Research programs:
A program to study potential new uses for our drug candidates in
clinical development in particular for new orphan indications and a program to identify novel
antibiotics targeting drug-resistant bacteria.
|
|
|
|